MSI-H Colorectal Cancer
14
1
6
3
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
21.4%
3 terminated out of 14 trials
50.0%
-36.5% vs benchmark
0%
0 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (14)
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform
Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies
Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
Dynamics of MSI and Genomic Profile of Colorectal Cancer In the Course of Immune Checkpoint Inhibitor Therapy
Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC.
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors
PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
Predictive Value of DNA Mismatch Repair System in Colorectal Cancers
Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer
Immunological Variables Associated to ICI Toxicity in Cancer Patients